Drug Trial Radar · NCT06534411
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,023
Actual
Start
Nov 5, 2024
Primary completion
Jun 2, 2026
Study completion Jul 9, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Aug 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
Conditions
- Diabetes Mellitus, Type 2
Interventions
CagrilintideDrug
Participants will receive once-weekly cagrilintide subcutaneously.
SemaglutideDrug
Participants will receive once-weekly semaglutide subcutaneously.
TirzepatideDrug
Participants will receive once-weekly tirzepatide subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycated Haemoglobin (HbA1c)Time frame: From baseline (week 0) to end of treatment (week 60)
- Relative Change in Body WeightTime frame: From baseline (week 0) to end of treatment (week 60)
Locations
163 sites in 14 countries. Site status is shown where the registry gives one.
Cahaba Research
Pelham, Alabama
Velocity Clinical Research-Phoenix
Phoenix, Arizona
AES Tucson DRS
Tucson, Arizona
Woodland Int. Research Group
Little Rock, Arkansas
Velocity Clin Res-Chula Vista
Chula Vista, California
John Muir Physicians Network
Concord, California
Diabetes & Endocrine Specialists - La Mesa
La Mesa, California
Velocity Clin Research LA
Los Angeles, California
Desert Oasis Healthcare
Palm Springs, California
Velocity Clin Res Santa Ana
Santa Ana, California
Velocity Clin Res - Panorama
Van Nuys, California
Optumcare Clinical Trials,LLC-Golden
Colorado Springs, Colorado
FEME Medical LLC
Washington D.C., District of Columbia
Tampa Bay Medical Research
Clearwater, Florida
AGA Clinical Trial
Hialeah, Florida
Bioclinical Research Alliance
Miami, Florida
New Horizon Research Center
Miami, Florida
South Broward Research LLC
Miramar, Florida
West Orange Endocrinology
Ocoee, Florida
Optimal Research Sites
Orange City, Florida
Center for Diab,Obes & Metab
Pembroke Pines, Florida
Javara Inc. / Privia Medical Group Georgia LLC
Fayetteville, Georgia
Clinical Invest Special_Gurnee
Gurnee, Illinois
Iowa Diabetes & Endo Res Ctr
West Des Moines, Iowa
Cotton-Oneill Diabetes and End
Topeka, Kansas
AES Minneapolis DRS
Richfield, Minnesota
Velocity Clin Res Gulfport
Gulfport, Mississippi
AES St. Louis DRS
St Louis, Missouri
Univ of Nebraska Medical CTR
Omaha, Nebraska
Velocity Clin Res Albuquerque
Albuquerque, New Mexico
Albany Medical College
Albany, New York
Carteret Medical Group
Morehead City, North Carolina
Piedmont Healthcare/Research
Statesville, North Carolina
Lillestol Research LLC
Fargo, North Dakota
Triad Research Institute
Norman, Oklahoma
Circuit Clinical - PMSI
Pottstown, Pennsylvania
Clinical Res Collaborative
Cumberland, Rhode Island
Velocity Clin Res Providence
East Greenwich, Rhode Island
Velocity Clin Res Gaffney
Gaffney, South Carolina
Holston Medical Group
Kingsport, Tennessee
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.